Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06157801 | ACTIVE NOT RECRUITING | Hereditary Cancer

Evaluation of Hereditary Cancer Educational Videos
Sponsor:

M.D. Anderson Cancer Center

Brief Summary:

To learn if educational videos can help participants be more informed about hereditary cancers (ones that run in the family).

Condition or disease

Hereditary Cancer

Intervention/treatment

Interview Study

Survey Study

Detailed Description:

Primary Objective Determine the impact of educational videos on: * Participant's hereditary cancer knowledge. * Participant's confidence to share hereditary cancer information with family members. Secondary Objective * Determine impact of educational videos on participant's confidence to undergo hereditary cancer screening. * Identify opportunities to tailor and improve the educational video's content, style, and understandability per participant preferences and feedback.

Study Type : OBSERVATIONAL
Estimated Enrollment : 43 participants
Official Title : Evaluation of Hereditary Cancer Educational Videos
Actual Study Start Date : 2024-04-05
Estimated Primary Completion Date : 2027-10-31
Estimated Study Completion Date : 2027-10-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Participants of The Harris Health System Lyndon B. Johnson (LBJ) Hospital outpatient oncology clinics (i.e., Gynecologic Oncology, Medical Oncology).
  • 2. 18 years of age or older.
  • 3. Speaks and/or reads English or Spanish.
  • 4. Has a pathogenic or likely pathogenic variant (mutation) in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM on germline genetic testing.
  • 5. Has a documented genetic testing results disclosure encounter (i.e. telephone call, follow-up appointment).
Exclusion Criteria
  • 1. No longer receives outpatient care at LBJ Hospital at time of recruitment.
  • 2. Has only a variant of uncertain significance in BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, and/or EPCAM.
  • 3. Has only a pathogenic or likely pathogenic variant in gene other than BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, or EPCAM.
  • 4. Is unwilling, unable, or requires a legally authorized representative to provide informed consent.
Evaluation of Hereditary Cancer Educational Videos

Location Details

NCT06157801

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Texas

MD Anderson Cancer Center

Houston, Texas, United States, 77030